A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015

Pulmongene

Status and phase: Completed; Phase 1

Conditions: Idiopathic Pulmonary Fibrosis

Treatments: Drug: PMG1015 Dose 5; Drug: PMG1015 Dose 4; Drug: Placebo; Drug: PMG1015 Dose 2; Drug: PMG1015 Dose 7; Drug: PMG1015 Dose 3; Drug: PMG1015 Dose 6; Drug: PMG1015 Dose 1

Study type: Interventional

Funder types: Industry

Identifiers

NCT05022771

PMG1015-AUS-101

Details and patient eligibility

About

This is a Phase 1A, first in human, randomized, double-blinded, placebo-controlled, dose escalation study of PMG1015 in healthy adult volunteers. PMG1015 is a monoclonal antibody, being developed as a novel therapeutic treatment for patients with Idiopathic Pulmonary fibrosis (IPF). This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PMG1015 after Single ascending doses (SAD).

Full description

Participants will be enrolled and randomized into 1 of 7 cohorts in a double-blind manner.

Enrollment: 54 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Healthy male or non-pregnant, non-lactating female volunteers, between 18 and 60 years of age, inclusive at the time of informed consent.
2. Body mass index (BMI) between 17.5 and 32.0 kg/m2 (inclusive) and body weight between 50 and 100 kg for males and between 45 and 100 kg for females.
3. No clinically significant clinical laboratory values (Hematology, coagulation, biochemistry and urinalysis) at the discretion of the PI.
4. Females of child bearing potential must use an acceptable, highly effective double contraception and have a negative pregnancy test at Screening and Day-1.
5. Documented evidence of surgical sterilization at least 6 months prior to screening for women or vasectomy at least 90 days prior to screening.
6. Women not of child bearing potential must be menopausal for >/= 12 months.
7. Males must not donate sperms for at least 90 days after PMG1015 administration.

Exclusion criteria

1. History or evidence of clinically significant condition, including but not limited to any cardiovascular, gastrointestinal, endocrinologic, hematologic, psychiatric, renal disease, musculoskeletal, infectious, or neurological condition or any chronic medical condition and/or other major disease, as determined by the PI.
2. A PR < 40 or > 100 beats per minute, mean systolic blood pressure (SBP) > 140 mmHg, or mean diastolic blood pressure (DBP) > 95 mmHg .
3. A mean corrected QT interval using Fridericia's formula (QTcF) interval at Screening > 450 ms in males and > 470 ms in females. If the mean QTcF exceeds these limits, one additional triplicate ECG will be performed.
4. Any clinically significant abnormalities in rhythm, conduction, or morphology of the resting ECG and any abnormalities in the 12-lead ECG that, in the judgment of the PI, may interfere with the interpretation of QTc-interval changes, including abnormal ST-T wave morphology or left ventricular hypertrophy.
5. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or creatinine > 1.5 × the upper limit of the normal range (ULN) or total bilirubin or lymphocyte counts > ULN.
6. Participants with a positive toxicology screening panel or alcohol breath test on Screening/Day-1.
7. Participants with a history of substance abuse or dependency or history of recreational IV drug use over the last 2 years.
8. Plasma donation/Blood donation or significant blood loss within 60 days prior to the first IP administration.
9. Use of any IP (including other investigational mAb products) or investigational medical device within 30 days prior to Screening or 5 half-lives of the product (whichever is the longest) or participation in more than 4 investigational drug studies within 1 year prior to screening.
10. Major surgery (general anesthetic) within 3 months or minor surgery (local anesthetic) within 1 month prior to IP administration, or planned surgery during the study period, which is determined by the PI to be clinically relevant.
11. Fever or symptomatic bacterial or viral infection.
12. Participants who have received live vaccines or attenuated vaccines within 1 month before dosing.
13. Participants with any active malignancy or history of malignancy within 5 years prior to enrolment.
14. Use of any other prescription medications.
15. History of anaphylaxis, allergic reactions to the excipients of IP, asthma.
16. Positive blood screen for HIV1/2 antibody, Hepatitis B surface antigen, hepatitis C virus, or syphilis at screening.
17. Participants with an inability to tolerate venous access.
18. Pregnant or lactating at Screening or planning to become pregnant (self or partner) at any time during the study, including the follow-up period.
19. An employee of Pulmongene or Novotech (Australia) Pty Ltd.
20. Participant is unwilling to abstain from alcohol beginning 48 hours prior to admission to the CRU and while resident at the CRU.
21. Any other condition or finding that in the opinion of the PI or designee would put the participant or study conduct at risk.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

54 participants in 7 patient groups

Single Ascending Doses Cohort 1a

Experimental group

Description:

Subjects will receive either Dose level 1 of PMG1015 or Placebo

Treatment:

Drug: PMG1015 Dose 1

Drug: Placebo

Single Ascending Doses Cohort 1b

Experimental group

Description:

Subjects will receive either Dose level 2 of PMG1015 or Placebo

Treatment:

Drug: Placebo

Drug: PMG1015 Dose 2

Single Ascending Doses Cohort 1c

Experimental group

Description:

Subjects will receive either Dose level 3 of PMG1015 or Placebo

Treatment:

Drug: Placebo

Drug: PMG1015 Dose 3

Single Ascending Doses Cohort 1d

Experimental group

Description:

Subjects will receive either Dose level 4 of PMG1015 or Placebo

Treatment:

Drug: Placebo

Drug: PMG1015 Dose 4

Single Ascending Doses Cohort 1e

Experimental group

Description:

Subjects will receive either Dose level 5 of PMG1015 or Placebo

Treatment:

Drug: Placebo

Drug: PMG1015 Dose 5

Single Ascending Doses Cohort 1f

Experimental group

Description:

Subjects will receive either Dose level 6 of PMG1015 or Placebo

Treatment:

Drug: PMG1015 Dose 6

Drug: Placebo

Single Ascending Doses Cohort 1g

Experimental group

Description:

Subjects will receive either Dose level 7 of PMG1015 or Placebo

Treatment:

Drug: Placebo

Drug: PMG1015 Dose 7